Liposomes for pulmonary administration
The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 μm and 5 μm, preferably between 0.2 μm and 2.0 μm, and the median aerodynamic mass diameter of aerosol particles comprising the liposomes is between 1 μm and 6 μm, preferably between 1.5 μm and 5 μm, in particular preferably between 2 μm and 4.5 μm. It is further in particular advantageous if the liposomes comprise an atomization stability of greater than 50%, preferably greater than 75%, in particular preferably greater than 80%, and if the transition temperature is greater than 37° C., preferably greater than 45° C., in particular preferably greater than 50° C.
1. A method of pulmonary administration comprising administering to a subject in need thereof via inhalation a liposomal formulation comprising:
A) liposomes comprising:
i) a first phospholipid, which is disteaorylphosphatidylcholine;
ii) a second phospholipid selected from the group consisting of dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, and dipalmitoylphosphatidylethanolamine; and
iii) cholesterol; and
B) an aqueous solution comprising at least one of an active agent and a dye, said aqueous solution being encapsulated inside said liposomes, wherein a molar ratio between the first phospholipid and the second phospholipid in the liposomes is from 2:1 to 6:1, wherein a molar ratio between a) the first and the second phospholipids and b) the cholesterol in the liposomes is from 3:1 to 6:1, wherein said administering comprises inhalation of said liposomal formulation after nebulization, and wherein a stability of said liposomes upon nebulization is at least 80%.
2. The method of claim 1 , wherein the liposomes consist of the first phospholipid, the second phospholipid, and the cholesterol.
3. The method of claim 1 , wherein the second phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine and dipalmitoylphosphatidylcholine.
4. The method of claim 1 , wherein a mass median aerodynamic diameter of aerosol particles produced by said nebulizing is between 1 μm and 6 μm.
5. The method of claim 4 , wherein the mass median aerodynamic diameter of aerosol particles produced by said nebulizing is between 1.5 μm and 5 μm.
6. The method of claim 5 , wherein the mass median aerodynamic diameter of aerosol particles produced by said nebulizing is between 2 μm and 4.5 μm.
7. The method of claim 1 , wherein a size of the liposomes after the nebulizing differs from a size of the liposomes before the nebulizing by less than 1 μm.
8. The method of claim 7 , wherein the size of the liposomes after the nebulizing differs from the size of the liposomes before the nebulizing by less than 0.2 μm.
9. The method of claim 1 , wherein said nebulizing is performed by a piezoelectric nebulizer.
10. The method of claim 1 , wherein said nebulizing is performed by an air-jet nebulizer.
11. The method of claim 1 , wherein said nebulizing is performed by an ultrasonic nebulizer.
12. The method of claim 1 , wherein a size of said liposomes ranges between 0.05 μm and 5 μm.
13. The method of claim 12 , wherein a size of said liposomes ranges between 0.2 μm and 2.0 μm.
14. The method of claim 1 , wherein a phase transition temperature of the liposomes is higher than 37° C.
15. The method of claim 14 , wherein the phase transition temperature of the liposomes is higher than 45° C.
16. The method of claim 15 , wherein the phase transition temperature of the liposomes is higher than 50° C.
17. The method of claim 1 , wherein the active agent is an image-producing agent.
18. The method of claim 1 , wherein the active agent is a radioactive agent.
19. The method of claim 1 , wherein the active agent is a contrast agent.
20. The method of claim 1 , wherein the active agent comprises magnetic particles.
21. The method of claim 1 , wherein the active agent comprises treprostinil.
22. The method of claim 1 , wherein the active agent comprises iloprost.
23. The method of claim 1 , wherein the active agent comprises sildenafil.
24. The method of claim 1 , wherein the liposomal formulation is a liposomal dispersion, which comprises an aqueous medium, in which the liposomes are dispersed.